ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Shanghai Pharmaceuticals Holding Co., Ltd clinical trials

Also known as SPH.

Part of Shanghai Shangshi (Group) Co., Ltd., which holds 38.76% as of 2025-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 41 studies whose lead sponsor is Shanghai Pharmaceuticals Holding Co., Ltd or the company grouped under it. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Shanghai Pharmaceuticals with China Resources Pharmaceutical Group and Jiangsu HengRui Medicine →

Pipeline: 3 programs

Each counted once: 3 with a study Shanghai Pharmaceuticals Holding Co., Ltd leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 4 (approved, new studies)

The 3 programs — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Shanghai Pharmaceuticals Holding Co., Ltd’s own registered studies; Shanghai Pharmaceuticals Holding Co., Ltd’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Shanghai Pharmaceuticals Holding Co., Ltd’s studies test, most open studies first — 13 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 3 more

Coming up

11 of Shanghai Pharmaceuticals Holding Co., Ltd’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 10D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

All 11

Show 6 more

Add all 11 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 41 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1537%Recruiting 13 · Not yet recruiting 2
  • Completed2049%
  • Stopped early25%Suspended 1 · Withdrawn 1
  • Status unknown or other410%

Phase

  • Phase 220
  • Phase 119
  • Early Phase 14
  • Phase 43
  • Phase 33

Where

Over the years

  1. 10
  2. 11
  3. 12
  4. 13
  5. 14
  6. 15
  7. 16
  8. 17
  9. 18
  10. 19
  11. 20
  12. 21
  13. 22
  14. 723
  15. 24
  16. 25
  17. 226

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shanghai Pharmaceuticals Holding Co., Ltd.

  • Shanghai Pharmaceuticals Holding Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    35 studies
  • Techpool Bio-Pharma Co., Ltd.
    Acquired — became part of Shanghai Pharmaceuticals Holding Co., Ltd, Aug 21, 2018 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →

Studies

Recruiting first, then most recently updated. Showing 41 of 41.